Brent Davis, MD
Interventional Cardiology · Tyler, TXNPI 1871588012
Payments from drug & device makers
What this record shows
22 manufacturers reported payments, led by Edwards Lifesciences at 32.0% of the total.
Across 247 payments — averaging $43.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$3K
- Abbott$3K
- Cardiovascular Systems Inc.$2K
- Novartis$848
- Medtronic$732
- Shockwave Medical, Inc$465
- plus $856 from 16 others
Across 104 payments — averaging $2055.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$173K
- Biotronik Inc.$25K
- AstraZeneca$16K
What the payments were for
- Travel & lodging$4,34740%
- Food & beverage$6,49160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 59 | $3,463 |
| Abbott | 30 | $2,803 |
| Cardiovascular Systems Inc. | 13 | $1,670 |
| Novartis | 49 | $848 |
| Medtronic(2 entities) | 28 | $732 |
| Shockwave Medical, Inc | 28 | $465 |
| Cvrx, Inc. | 3 | $143 |
| Inari Medical, Inc. | 2 | $136 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $117 |
| Amgen | 7 | $115 |
| Johnson & Johnson | 5 | $68 |
| Amarin Pharma, Inc. | 3 | $44 |
| Pfizer | 2 | $37 |
| Boston Scientific | 2 | $34 |
| Abiomed | 1 | $31 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Siemens Medical Solutions USA, Inc. | 1 | $25 |
| CMP Pharma, Inc. | 2 | $25 |
| Merck | 1 | $20 |
| Boehringer Ingelheim | 1 | $14 |
| Novo Nordisk | 1 | $13 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Peripheral Orbital Atherectomy System$1,432
- SAPIEN 3 Ultra RESILIA$1,113
- Mitra Clip system$1,012
- TRICLIP$693
- DRAGONFLY OPSTAR$162
- COREVALVE EVOLUT R$151
- SYMPLICITY G3$147
- MitraClip System$143
- AVEIR$122
- FLOWTRIEVER CATHETER, S$111
- CT THROMBECTOMY SYSTEM KIT$111
- Barostim Neo System$107
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$105
How this compares
$10,838 in reported general payments places this provider in the 55th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 597 | $593,199 |
| JardianceEmpagliflozin | 178 | $124,842 |
| EntrestoSacubitril/Valsartan | 111 | $119,345 |
| BrilintaTicagrelor | 170 | $101,542 |
| MultaqDronedarone Hcl | 94 | $100,821 |
| XareltoRivaroxaban | 81 | $82,533 |
| Repatha SureclickEvolocumab | 57 | $57,092 |
| VascepaIcosapent Ethyl | 41 | $16,721 |
| Praluent PenAlirocumab | 20 | $15,131 |
| FarxigaDapagliflozin Propanediol | 14 | $12,418 |
| Ranolazine ErRanolazine | 133 | $11,081 |
| Metoprolol Succinate | 653 | $8,699 |
| LivaloPitavastatin Calcium | 18 | $7,381 |
| Atorvastatin Calcium | 686 | $5,861 |
| Icosapent Ethyl | 19 | $5,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lipitor | $37 | $597,467608 claims |
| Boehringer IngelheimJardiance | $14 | $124,842178 claims |
| NovartisEntresto | $848 | $119,345111 claims |
| Johnson & JohnsonXarelto | $68 | $82,53381 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Tyler
- Jeffrey CarrTyler$1.9M
- Preetham Reddy MuskulaTyler$91K
- Juan GranadaHouston$4.1M
- Vamsi KrishnaKyle$2M
- John IsaacHouston$1.8M
- Robert ChiltonSan Antonio$1.3M
- Sameh SayfoPlano$1M
- Srinivasa PotluriPlano$781K
- Karim Al-AziziPlano$734K
- Robert StolerDallas$587K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.